JP2023512036A5 - - Google Patents
Info
- Publication number
- JP2023512036A5 JP2023512036A5 JP2022546059A JP2022546059A JP2023512036A5 JP 2023512036 A5 JP2023512036 A5 JP 2023512036A5 JP 2022546059 A JP2022546059 A JP 2022546059A JP 2022546059 A JP2022546059 A JP 2022546059A JP 2023512036 A5 JP2023512036 A5 JP 2023512036A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nectin
- binding protein
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025077110A JP2025121970A (ja) | 2020-01-31 | 2025-05-07 | 癌の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968175P | 2020-01-31 | 2020-01-31 | |
| US62/968,175 | 2020-01-31 | ||
| PCT/EP2021/051938 WO2021151984A1 (en) | 2020-01-31 | 2021-01-28 | Treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077110A Division JP2025121970A (ja) | 2020-01-31 | 2025-05-07 | 癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512036A JP2023512036A (ja) | 2023-03-23 |
| JP2023512036A5 true JP2023512036A5 (https=) | 2024-02-05 |
| JP7682553B2 JP7682553B2 (ja) | 2025-05-26 |
Family
ID=74494891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546059A Active JP7682553B2 (ja) | 2020-01-31 | 2021-01-28 | 癌の処置 |
| JP2025077110A Pending JP2025121970A (ja) | 2020-01-31 | 2025-05-07 | 癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077110A Pending JP2025121970A (ja) | 2020-01-31 | 2025-05-07 | 癌の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12594343B2 (https=) |
| EP (2) | EP4096717B1 (https=) |
| JP (2) | JP7682553B2 (https=) |
| CN (1) | CN114845740A (https=) |
| AU (2) | AU2021213421B2 (https=) |
| CA (1) | CA3160557A1 (https=) |
| DK (1) | DK4096717T3 (https=) |
| ES (1) | ES3014740T3 (https=) |
| WO (1) | WO2021151984A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023541637A (ja) * | 2020-09-15 | 2023-10-03 | シンアフィックス ビー．ブイ． | 抗体－エクサテカンコンジュゲート |
| MX2023005873A (es) * | 2020-11-25 | 2023-06-05 | Innate Pharma | Tratamiento del cancer. |
| KR20240035378A (ko) * | 2021-03-31 | 2024-03-15 | 이머전스 세라퓨틱스 아게 | 항-넥틴-4 항체 엑사테칸 접합체 |
| EP4086284A1 (en) * | 2021-05-07 | 2022-11-09 | Emergence Therapeutics AG | Anti-nectin-4 antibody exatecan conjugates |
| WO2022262516A1 (zh) * | 2021-06-18 | 2022-12-22 | 北京海步医药科技有限公司 | 连接子及其缀合物 |
| IL313805A (en) * | 2021-12-28 | 2024-08-01 | Beigene Switzerland Gmbh | Drug antibody conjugates |
| US20250205353A1 (en) * | 2022-03-23 | 2025-06-26 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| CN119317447A (zh) | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| JP2025517476A (ja) * | 2022-05-25 | 2025-06-05 | イナート・ファルマ・ソシエテ・アノニム | ネクチン－４結合剤 |
| EP4285935A1 (en) * | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| US20230408497A1 (en) * | 2022-06-20 | 2023-12-21 | Sysmex Corporation | Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance |
| WO2024012536A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体、其抗体药物偶联物及应用 |
| WO2024012541A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物及应用 |
| EP4309676A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| US12576154B2 (en) * | 2022-08-01 | 2026-03-17 | Philochem Ag | Conjugates of PSMA-binding moieties with cytotoxic agents |
| EP4324849A1 (en) * | 2022-08-18 | 2024-02-21 | Emergence Therapeutics AG | Humanized anti-nectin-4 antibodies |
| EP4344707A1 (en) * | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
| WO2024078449A1 (en) * | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| WO2024098066A1 (en) * | 2022-11-04 | 2024-05-10 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
| JP2025537278A (ja) * | 2022-11-09 | 2025-11-14 | オービーアイ ファーマ，インコーポレイテッド | 抗体－薬物コンジュゲートの工学のためのグリコシンターゼのバリアント |
| WO2024191598A1 (en) * | 2023-03-10 | 2024-09-19 | Emory University | Labeled amplifier oligonucleotides for detecting low or ultra low expression of cancer markers and uses in managing cancer treatments |
| CN118666946A (zh) * | 2023-03-15 | 2024-09-20 | 上海亲合力生物医药科技股份有限公司 | 连接子及使用其的偶联药物、抗体偶联药物及其应用 |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| AU2024304180A1 (en) * | 2023-06-13 | 2026-01-08 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| JP7689606B2 (ja) * | 2023-06-20 | 2025-06-06 | イーライ リリー アンド カンパニー | ネクチン－４抗体及び抗体－薬物コンジュゲート |
| EP4735047A1 (en) * | 2023-06-28 | 2026-05-06 | Université de Tours | Pegylated linkers and uses thereof |
| TW202530249A (zh) | 2023-09-29 | 2025-08-01 | 美商雅克提斯腫瘤學公司 | 小蛋白、結合物及其用途 |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534102A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| WO2025078881A2 (en) * | 2023-10-13 | 2025-04-17 | Ligachem Biosciences Inc. | Anti-claudin 18.2 antibody drug conjugates comprising topoisomerase i inhibitor and uses thereof |
| US20250121084A1 (en) * | 2023-10-17 | 2025-04-17 | Adc Therapeutics Sa | Anti-claudin-6 conjugates |
| FR3155708A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| FR3155709A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| US20250186604A1 (en) * | 2023-12-06 | 2025-06-12 | Adc Therapeutics Sa | Anti-psma antibody conjugates |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| FR3164899A1 (fr) * | 2024-07-24 | 2026-01-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| EP4732850A1 (en) * | 2024-10-25 | 2026-04-29 | Antelope Therapeutics SAS | Antibody-drug conjugates and their uses |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| JP4638225B2 (ja) | 2002-05-30 | 2011-02-23 | ザ スクリプス リサーチ インスティテュート | 銅を触媒とするアジドとアセチレンのライゲーション |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| EP2222341B1 (en) | 2007-11-21 | 2015-02-25 | University Of Georgia Research Foundation, Inc. | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds |
| US20110301056A1 (en) | 2008-12-12 | 2011-12-08 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
| WO2011121453A2 (en) | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| MX347954B (es) * | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| CN107106701B (zh) | 2014-10-03 | 2020-11-06 | 西纳福克斯股份有限公司 | 磺酰胺接头、其缀合物及制备方法 |
| EP3218009B1 (en) | 2014-10-14 | 2021-04-07 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
| EP3347048B1 (en) | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| CA3044898C (en) * | 2016-11-25 | 2022-04-05 | Mabwell (shanghai) Bioscience Co., Ltd. | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof |
| CN110392697A (zh) | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
| WO2018226578A1 (en) | 2017-06-05 | 2018-12-13 | Agensys, Inc. | Nectin-4-binding proteins and methods of use thereof |
| KR20260011205A (ko) | 2017-10-05 | 2026-01-22 | 소니그룹주식회사 | 프로그램가능한 중합체성 약물 |
| JP7381478B2 (ja) | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CA3114474A1 (en) | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| CA3128571A1 (en) | 2019-03-19 | 2020-09-24 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
| SG11202110922QA (en) * | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| CA3085001C (en) | 2019-05-20 | 2021-10-05 | Mabplex International, Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
| US12398206B2 (en) | 2019-10-07 | 2025-08-26 | Université D'aixmarseille | Antibodies having specificity for nectin-4 and uses thereof |
| KR20220106779A (ko) | 2019-11-25 | 2022-07-29 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)를 사용한 암의 치료 |
| CN113527486B (zh) | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| CN115768798A (zh) | 2020-06-18 | 2023-03-07 | 生物蛋白有限公司 | 条件活性抗粘附分子-4(nectin-4)抗体 |
| EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| JP2023541637A (ja) | 2020-09-15 | 2023-10-03 | シンアフィックス ビー．ブイ． | 抗体－エクサテカンコンジュゲート |
| MX2023005873A (es) | 2020-11-25 | 2023-06-05 | Innate Pharma | Tratamiento del cancer. |
| JP2025517476A (ja) | 2022-05-25 | 2025-06-05 | イナート・ファルマ・ソシエテ・アノニム | ネクチン－４結合剤 |
-
2021
- 2021-01-28 EP EP21702624.4A patent/EP4096717B1/en active Active
- 2021-01-28 DK DK21702624.4T patent/DK4096717T3/da active
- 2021-01-28 AU AU2021213421A patent/AU2021213421B2/en active Active
- 2021-01-28 CN CN202180007603.2A patent/CN114845740A/zh active Pending
- 2021-01-28 WO PCT/EP2021/051938 patent/WO2021151984A1/en not_active Ceased
- 2021-01-28 US US17/796,707 patent/US12594343B2/en active Active
- 2021-01-28 CA CA3160557A patent/CA3160557A1/en active Pending
- 2021-01-28 EP EP24211980.8A patent/EP4512478A3/en active Pending
- 2021-01-28 ES ES21702624T patent/ES3014740T3/es active Active
- 2021-01-28 JP JP2022546059A patent/JP7682553B2/ja active Active
-
2025
- 2025-04-14 AU AU2025202617A patent/AU2025202617A1/en active Pending
- 2025-05-07 JP JP2025077110A patent/JP2025121970A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512036A5 (https=) | ||
| Lambert et al. | Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review | |
| Perez et al. | Antibody–drug conjugates: current status and future directions | |
| Senter | Potent antibody drug conjugates for cancer therapy | |
| JP2021102648A (ja) | 抗ｆｏｌｒ１免疫複合体投与計画 | |
| JP2018520991A5 (https=) | ||
| US20250281634A1 (en) | Conjugates comprising a phosphorus (v) and a drug moiety | |
| JP2024075771A (ja) | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 | |
| AU2016203839A1 (en) | Antibody-drug conjugates | |
| JP2018520091A5 (https=) | ||
| JP2024501121A5 (https=) | ||
| Lee et al. | Antibody-drug conjugates in gynecologic malignancies | |
| JP7264831B2 (ja) | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用 | |
| US20210283267A1 (en) | Therapeutic methods using antibody drug conjugates (adcs) | |
| Amani et al. | ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies | |
| Xie et al. | Antibody-drug conjugates for the therapy of thoracic malignancies | |
| Cheng et al. | Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors | |
| Zhang et al. | Evaluation of double self-immolative linker-based antibody–drug conjugate FDA022-BB05 with enhanced therapeutic potential | |
| Kommineni et al. | Antibody drug conjugates: development, characterization, and regulatory considerations | |
| JP2024539989A5 (https=) | ||
| JP2025535447A5 (https=) | ||
| JPWO2021251459A5 (https=) | ||
| Deng et al. | Recent advances in antibody-drug conjugates for breast cancer treatment | |
| Sevilla-Carrillo et al. | Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology | |
| JP2024528917A5 (https=) |